Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 0574/96 (Deoxytetracyclines/AMERICAN CYANAMID) 30-07-1999
Facebook X Linkedin Email

T 0574/96 (Deoxytetracyclines/AMERICAN CYANAMID) 30-07-1999

European Case Law Identifier
ECLI:EP:BA:1999:T057496.19990730
Date of decision
30 July 1999
Case number
T 0574/96
Petition for review of
-
Application number
92114281.6
IPC class
C07C 237/26
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN AND MEMBERS (B)

Download and more information:

Decision in EN 156.37 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines

Applicant name
AMERICAN CYANAMID COMPANY
Opponent name
-
Board
3.3.01
Headnote
-
Relevant legal provisions
European Patent Convention Art 84 1973
European Patent Convention Art 111(1) 1973
Keywords
Clarity (yes) - complex claims not unclear
Catchword
Clarity under Article 84 EPC is not at stake in a case of mere complexity of a claim, provided the subject-matter for which protection is sought and the scope thereof are clear and unambiguous for a person skilled in the art, either per se or in the light of the description, since complexity as such is not equivalent to lack of clarity.
Cited decisions
-
Citing decisions
T 1020/98
T 1020/98
T 1020/98
T 1020/98

I. The appeal lodged on 28 March 1996 lies from the decision of the Examining Division posted on 30. January 1996 refusing European patent application No. 92 114 281.6 (European publication No. 0 536 515).

II. The decision of the Examining Division was based on claims 1 to 20 of the application as filed and annexed thereto. Claims 1 and 11 read as follows:

"1. A compound of the formula:

FORMULA

wherein:

X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; and when X = NR1R2 and R1 = hydrogen,

R2 = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when R1 = methyl or ethyl,

R2 = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R1 = n-propyl,

R2 = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R1 = 1-methylethyl,

R2 = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R1 = n-butyl,

R2 = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R1 = 1-methylpropyl,

R2 = 2-methylpropyl;

R is selected from R4(CH2)nCO- or R4'(CH2)nSO2-;

and when R = R4(CH2)nCO- and n=0,

R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; alpha-amino-(C1-C4)alkyl group selected from aminomethyl, alpha-aminoethyl, alpha-aminopropyl or alpha-aminobutyl; carboxy(C2-C4)-alkylamino group selected from aminoacetic acid, alpha-aminobutyric acid or alpha-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; alpha-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, alpha-hydroxyethyl or alpha-hydroxy-1-methylethyl or alpha-hydroxypropyl; alpha-mercapto(C1-C3)alkyl group selected from mercaptomethyl, alpha-mercaptoethyl, alpha-mercapto-1-methylethyl or alpha-mercaptopropyl; halo(C1-C3)alkyl group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto: FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, alpha-naphthyl, beta-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ]; (C1-C4)alkoxy group; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, alpha-naphthyl or beta-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R = R4(CH2)nCO- and n=1-4, R4 is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcar- bonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; (C1-C4)alkoxy group; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino); (C7-C10)aralkyloxy group; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C8)aralkylthio group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O,S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; (C2-C5)azacycloalkyl group; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, alpha-aminopropionic acid, alpha-aminobutyric acid and their optical isomers; alpha-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, alpha-hydroxyethyl or alpha-hydroxy-1-methylethyl or alpha-hydroxypropyl; halo(C1-C3) alkyl group; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-ar yl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or

-(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)n, n=2-6, or

-(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R = R4'(CH2)nSO2- and n = 0, R4' is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group; halo(C1-C3)alkyl group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto: FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or

-(CH2)2W-(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R = R4'(CH2)nSO2- and n= 1-4, R4' is selected from hydrogen; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy group; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)n- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or -(CH2)2W(CH2)2- wherein W is selected from -N(C1-C3)alkyl [straight or branched], -NH, -NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio or n-propylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C8)aralkylthio group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O,S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; hydroxy group, mercapto group; mono- or di- straight or branched (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; halo(C1-C3)alkyl group; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; (C7-C9)aralkyl group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom: FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; or -(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, alpha-naphthyl or beta-naphthyl; (C7-C9)aralkyl group; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z = N, O, S or Se ,

or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

FORMULA

Z or Z1 = N, O, S or Se ,

or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:

FORMULA

(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; or -(CH2)nCOOR7' where n=0-4 and R7' is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, alpha-naphthyl or beta-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are -(CH2)2W(CH2)2-, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl [straight or branched], -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

11. The compound according to Claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide sulfate; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide monohydrochloride; [4S-(4alpha,12aalpha)]-9-(Acetylamino)-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)] -4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(trifluoroacetyl)amino]-2- naphthacenecarboxamide sulfate; [4S-(4alpha, 12aalpha)]-7-(Diethylamino)-4-(dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamidesulfate (1:2); [4S-(4alpha,12aalpha)]-9-(Acetylamino)-7- (diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide sulfate (1:2); [4S-(4alpha,12aalpha)]-7-(Diethylamino)-4- (dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide; [4S-(4alpha, 12aalpha)]-9-(Acetylamino)-7-(diethylamino)-4- (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydrox y-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)] -4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7- iodo-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9- (formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2- naphthacenecarboxamide sulfate; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-9- [(methoxyacetyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; 4S-(4alpha,12aalpha)]-9- [(4-Bromo-1-oxobutyl)amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; 4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(1-oxo-2-propenyl)amino]-2- naphthacenecarboxamide; 4S-(4alpha,12aalpha)]-9- [[(Acetyloxy)acetyl]amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide sulfate; 4S-(4alpha, 12aalpha)]-9-(Benzoylamino)-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11, 2a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; 4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(4-methoxybenzoyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha))]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(2-methylbenzoyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[(2-fluorobenzoyl) amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(pentafluorobenzoyl)amino]-1,11-dioxo-2- naphthacenecarboxamide hydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-9-[[3-(trifluoromethyl) benzoyl]amino]-2-naphthacenecarboxamide;

[4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [(2-furanylcarbonyl)amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy1,11-dioxo-9- [(2-thienylcarbonyl)amino]-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(4-nitrobenzoyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 9-[(4-Aminobenzoyl)amino]-4,7-bis- dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamidesulfate; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-9-[[(4- dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide; [7S-(7alpha, 10aalpha)]-[2-[[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester; [4S-(4alpha,12aalpha)]- 9-[(Aminoacetyl)amino]-4,7-bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono(trifluoroacetate); [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(phenylsulfonyl)amino]-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-9-[[(4-Chlorophenyl) sulfonyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5, 5a,6,11,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9-[(3- nitrophenyl)sulfonyl]amino-1,11-dioxo-2- naphthacenecaboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9-[[(4- nitrophenyl)sulfonyl]amino]-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4alpha,12a alpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(2-thienylsulfon [4S-(4alpha,12aalpha)]-9[[(2- (Acetylamino)-4-methyl-5-thiazolylsulfonyl]amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[(ethylsulfonyl)amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (formylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-1,11-dioxo-N-(1- pyrrolidinylmethyl)-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-9-[(methanesulfonyl)amino]-1,11- dioxo-2-naphthacenecarboxamide; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-9-[[(phenylmethoxy)acetyl]amino]-2- naphthacenecarboxamide; [7S-(7alpha,10aalpha)]- [[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a, 6,6a,7,10,10a,12-octahydro-1,8,10a,11- tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]oxoacetic acid ethyl ester; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [(hydroxyacetyl)amino]-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[[(methylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboximide hydrochloride; [4S-(4alpha,12aalpha)]-4-(Dimethylamino)-9- (acetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2- naphthacenecarboxamide sulfate; [7S(7alpha, 10aalpha)]-[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid methyl ester; [7S-(7alpha,10aalpha)]-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid (2-diethylamino)ethyl ester; [7S-(7alpha,10aalpha)][9-(Aminocarbonyl)- 4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid ethenyl ester; [7S- (7alpha,10aalpha)]-[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid 2-propenyl ester; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide sulfate; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-9-[(methoxyacetyl)amino]-1,11-dioxo- 2-naphthacenecarboxamide hydrochloride; [4S-(4alpha,12aalpha)]-9-[(4-Bromo-1-oxobutyl) amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide sulfate; [4S-(4alpha,12aalpha)]-9-[[(Acetyloxy)acetyl] amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide; [4S-(4alpha, 12aalpha)]-9-(Benzoylamino)-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide sulfate; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-9-[[3-(trifluoromethyl)benzoyl]amino]-2- naphthacenecarboxamide hydrochloride; [4S- (4alpha,12aalpha)]-9-[(4-Aminobenzoyl)amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[[(4-dimethylamino) benzoyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide hydrochloride; [7S- (7alpha,10aalpha)]-[2-[[9-(Aminocarbonyl)-4, 7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester hydrochloride; [4S- (4alpha,12aalpha]-9-[(Aminoacetyl)amino]-4,7-bis- dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[(ethylsulfonyl)amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-9-[(methanesulfonyl) amino]-1,11-dioxo-2-naphthacenecarboxamide sulfate; [4S-(4alpha,12aalpha)]-4,7-Bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [[(phenylmethoxy)acetyl]amino]-2- naphthacenecarboxamide hydrochloride; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 9-[(hydroxyacetyl)amino]-1,11-dioxo-2- naphthacenecarboxamide sulfate; [4S-(4alpha, 12aalpha)]-4-(Dimethylamino)-9-(acetylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-7-iodo-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [7S-(7alpha,10aalpha)]- [9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6, 6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester sulfate; [7S-(7alpha,10aalpha)]-[9- (Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a, 7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]carbamic acid (2-diethylamino)ethyl ester hydrochloride; [7S-(7alpha,10aalpha)]-[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid ethenyl ester sulfate; [7S-(7alpha,10aalpha)]-[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]carbamic acid 2-propenyl ester hydrochloride; [4S-(4alpha,12aalpha]-4,7-Bis (dimethylamino)-9-[[(diethylamino)acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate; [4S(4alpha,12aalpha]-4,7-Bis (dimethylamino)-9-[[(diethylamino)acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride; [4S-(4alpha,12aalpha]-4,7-Bis (dimethylamino)-9-[[(diethylamino)acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- (chloroacetylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-9- [(Chloroacetyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-9- [(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-9- [(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (free base); [4S-(4alpha,12aalpha)]-9- [(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide; [4S-(4alpha,12aalpha)]-9- [(2-Bromo-1-oxopropyl)amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide hydrobromide; [4S- (4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)amino]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide hydrobromide; [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetrahydroxy-9- [[(methylamino)acetyl]amino]-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride; [7S- (7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]-4-morpholineacetamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-9-[[(ethylamino)acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-9- [[(Cyclopropylamino)acetyl]amino]-4,7- bis(dimethylamino)-1,4,4a,5,5a,6,11,12aoctahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(butylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-9-[[(Diethylamino)acetyl] amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]-1-pyrrolidineacetamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [[[(2-methylpropyl)amino]acetyl]amino]-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]-1-piperidineacetamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[9- (Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a, 7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-1H-imidazole-1-acetamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [[(propylamino)acetyl]amino]-2- naphthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[2-(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-napthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-9- [[2-(methylamino)-1-oxopropyl]amino]-1,11-dioxo- 2-naphthacenecarboxamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12- octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]-alpha-methyl-1-pyrrolidineacetamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7- Bis(dimethylamino)-9-[[4-(dimethylamino)-1- oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2- napthacenecarboxamide dihydrochloride; [4S- (4alpha,12aalpha)]-9-[[(Butylmethylamino)acetyl] amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-9-[[(pentylamino)acetyl] amino]-2-naphthacenecarboxamide dihydrochloride; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-9-[[[(phenylmethyl)amino]acetyl]amino] -2-naphthacenecarboxamide dihydrochloride; [7S-(7alpha,10aalpha)]-N-[2-[[9- (Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a, 7,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12- dioxo-2-naphthacenyl]amino]-2-oxoethyl]glycine; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-N-(1-pyrrolidinylmethyl)-2- naphthacenecarboxamide; [4S-(4alpha,12aalpha)]- 4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-N-(4- morpholinylmethyl)-2-naphthacenecarboxamide; [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-N-(1-piperidinylmethyl)-2- naphthacenecarboxamide; [7S-(7alpha,10aalpha)]-N- [9-(Aminocarbonyl-4,7-bis(dimethylamino)-5,5a,6, 6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-napthacenyl]-1-azetidineacetamide; [4S-(4alpha,12aalpha)]-9-[[(Cyclobutylamino) acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide hydrochloride."

III. The Examining Division held that claims 1 and 11 did not meet the requirements of Article 84 EPC. More particularly, the Examining Division considered claim 1 to be unclear since it was not possible to establish with absolute certainty within a reasonable time whether any single compound fell within the scope of that claim due to Markush formulae formulated in a complex manner. Problems arose from the enormous length of the claim, the large number of variables often defined in terms of further variables and the manifold provisos. To combine these features caused the mental processes, which determined whether a compound was covered by the claim, to break down in confusion rendering it impossible for the claim to define the matter for which protection is sought. The complexity of a claim could not be increased indefinitely and still meet the requirements of Article 84 EPC. In such a case it must be possible to declare the claim prima facie unclear. With regard to claim 11 the long list of complex chemical names in that claim presented an undue burden on the person trying to establish whether a compound fell within the scope of that claim.

IV. The Appellant (Applicant) submitted that claims 1 and 11. did not lack clarity as stipulated by Article 84 EPC. More particularly, neither the complexity of the claims nor the time needed by a reader to establish whether or not a single compound fell within the scope of the claims were issues to be considered pursuant to Article 84 EPC. Claim 1 showed a clear and concise hierarchical construction which prevented any confusion of the skilled reader. The two polycyclic formulae of claim 1 had only four substituents (R, X, R5, R6). The substituent X had a very brief definition over 13 lines. The substituent R was defined hierarchically on the basis of the provisos:

(A) R = R4(CH2)nCO- and n=0, or

(B) R = R4(CH2)nCO- and n=1-4, or

(C) R = R4'(CH2)nSO2- and n = 0, or

(D) R = R4'(CH2)nSO2- and n= 1-4.

Those provisos were further defined on one to two pages each. Finally the substituents R5 and R6 were then defined on 3/4 of a page. Claim 11 had been written in accordance with standard chemical nomenclature which could not cause any lack of clarity.

V. The Appellant requested that the decision under appeal be set aside and that the case be remitted to the Examining Division for further prosecution. Auxiliarily he requested that oral proceedings be appointed in case the request was not held allowable.

1. The appeal is admissible.

2. The only issue arising from this appeal is whether or not claims 1 and 11 satisfy the requirement of clarity within the meaning of Article 84 EPC, which is stated in the decision under appeal as being the sole ground for refusal of the application.

3. Article 84 EPC

3.1. In the contested decision claim 1 comprising Markush-formulae has been objected to under the heading of clarity as being formulated in a so complex manner that it was impossible to establish within a reasonable time whether any single compound fell within the scope of that claim.

The Board observes that the European Patent Convention does not prescribe the absence of complexity from a claim as a legal requirement for a patent to be granted thereupon. The Board would also consider any such requirement as unreasonable, because if the nature of an invention to be patented is such that it cannot be claimed in a nutshell, this must be accepted.

For that reason, the Examining Division has based the objection to complexity on lack of clarity pursuant to Article 84 EPC. However, in the present case Article 84 EPC offers no basis for objecting that the claim is too complex. In the Board's judgement, complexity as such is not equivalent to lack of clarity. Clarity under Article 84 EPC is not at stake in a case of mere complexity of a claim provided the subject-matter for which protection is sought and the scope thereof are clear and unambiguous for a person skilled in the art, either per se or in the light of the description. Further, the Board cannot see from the decision under appeal what is meant by "within a reasonable time", apart from possibly that it takes longer than average to examine the subject-matter of the claim.

The Board noted furthermore that despite the rather unusual length of claim 1 the Examining Division did not challenge its conciseness, another requirement to be met under Article 84 EPC. Indeed Article 84 EPC cannot be construed in such a way that only inventions which are straightforward would have access to patent protection, whereas complex inventions would be locked out from that protection. It would be improper to refuse to examine that which applicants regard as their invention. This does not mean, however, that lack of conciseness could not arise in particular circumstances, since each case has to be decided on its own merits.

3.2. In the present case claim 1 is directed to compounds having either of two related polycyclic Markush-formulae indicated at the beginning of that claim on page 253, lines 5 to 15. Those formulae bear exclusively the four variable substituents X, R, R5 and R6 which are nested each one within another in a hierarchical order (see point II above). The key to the hierarchical order emerges from the ingenious use of semicolons, commas, round brackets and square brackets throughout that claim.

3.2.1. The substituent X is defined on page 253, lines 16 to 34 in a clear-cut hierarchical manner and has not been objected to in the decision under appeal. Thus, it is unnecessary for the Board to go into more detail on this matter.

3.2.2. The substituent R is defined on page 253, line 35 as representing either R4(CH2)nCO- or R4'(CH2)nSO2-, the respective substituents R4 and R4' and the index n being then specified each with respect to the following provisos:

(A) R = R4(CH2)nCO- and n=0 (page 253, line 36),

(B) R = R4(CH2)nCO- and n=1-4 (page 258, line 31),

(C) R = R4'(CH2)nSO2- and n = 0 (page 264, line 13), or

(D) R = R4'(CH2)nSO2- and n= 1-4 (page 266, line 18).

3.2.2.1. If proviso (A) applies, the substituent R4 is selected from the following list of first order starting with "hydrogen" on page 253, line 37 and ending with the "RaRbaminoxy group" on page 258, line 24 and indicating the alternative groups:

hydrogen; amino; monosubstituted amino; disubstituted amino; straight or branched (C1-C4)alkyl group; (C3-C6)cycloalkyl group; substituted (C3-C6)cycloalkyl group; (C6-C10)aryl group; substituted (C6-C10)aryl group; (C7-C9)aralkyl group ; alpha-amino-(C1-C4)alkyl group; carboxy(C2-C4)-alkylamino group; (C7-C9)aralkylamino group; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group; alpha-hydroxy(C1-C3)alkyl group; alpha-mercapto(C1-C3)alkyl group; halo(C1-C3)alkyl group; a heterocycle group; acyl or haloacyl group; (C1-C4)alkoxycarbonyl group; vinyl or substituted vinyl group; (C1-C4)alkoxy group; C6-aryloxy group; (C7-C10)aralkyloxy group; vinyloxy or substituted vinyloxy group; RaRbamino(C1-C4)alkoxy group; or RaRbaminoxy group.

3.2.2.1.1. Numerous groups of that list of first order are more narrowly defined by making a further selection from particular lists of second order consisting each of specific alternative groups.

For example, the "heterocyle group" comprised in the list of first order is to be selected from the list of second order starting on page 254, line 32, and ending on page 256, line 5, and consisting of five alternative groups, i.e. a five membered aromatic or saturated ring with one N, O, S or Se heteroatom as defined in two particular formulae, or a five membered aromatic ring with two N, O, S or Se heteroatoms as defined in two particular formulae, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom as defined in three particular formulae, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom.

The "acyl or haloacyl group" comprised in the list of first order is to be selected from the list of second order starting with the "acetyl" group on page 256, line 6, and ending with the "(heterocycle)carbonyl" group on page 256, line 10.

The substitution of the "substituted vinyl" group comprised in the list of first order is to be selected from the list of second order starting with the "(C1-C3)alkyl" group on page 257, line 24, and ending with the "heterocycle group" on page 257, line 30.

The substituents Ra and Rb contained in both "RaRbamino(C1-C4)alkoxy" and "RaRbaminoxy" groups of the list of first order, are defined in lists of second order as representing either a "straight or branched (C1-C4)alkyl" group (page 258, lines 18 and 25), or a "(CH2)n" group (page 258, lines 20 and 27), or a "-(CH2)2W(CH2)2-" group (page 258, lines 21 and 28).

3.2.2.1.2. Some groups of those lists of second order are more narrowly defined by making a further selection from particular lists of third order consisting each of specific alternative groups.

For example, the heterocycle of the "(heterocycle)carbonyl" group comprised in the list of second order on page 256, line 10, is to be selected from the list of third order starting on page 256, line 10, and ending on page 257, line 20, and consisting of five alternative groups, i.e. a five membered aromatic or saturated ring with one N, O, S or Se heteroatom as defined in two particular formulae, or a five membered aromatic ring with two N, O, S or Se heteroatoms as defined in two particular formulae, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom as defined in three particular formulae, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom.

The substitution of the "substituted (C6-C10)-aryl group" comprised in the list of second order on page 257, lines 26 and 27, is to be selected from the list of third order starting with "halo" on page 257, line 27, and ending with the "carboxy" group on page 257, line 29.

The "heterocycle group" comprised in the list of second order on page 257, line 30 is to be selected, in third order, from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom as defined in two particular formulae.

The group W of the "-(CH2)2W(CH2)2-" group comprised in the list of second order on page 258, lines 21 and 28 is to be selected from the lists of third order on page 258, lines 21 and 22 and page 258, lines 28 and 29 respectively, consisting of five alternative groups, i.e. -N(C1-C3)alkyl, -NH, -NOB, O or S.

3.2.2.1.3. Very few groups of those lists of third order are even more narrowly defined by making a further selection from particular lists of fourth order consisting each of specific alternative groups.

For example, the group B of the "NOB" group comprised in the list of third order on page 258, lines 22 and 28 is to be selected from the list of fourth order on page 258, lines 23 and 29, i.e. hydrogen or (C1-C3)alkyl.

3.2.2.2. If proviso (B) applies, the substituent R4 is selected from the following list of first order starting with "hydrogen" on page 258, line 31 and ending with the "RaRbaminoxy group" on page 264, line 4 and indicating the alternative groups:

hydrogen; amino; straight or branched (C1-C4)alkyl group; (C3-C6)cycloalkyl group; substituted (C3-C6)cycloalkyl group; (C6-C10)aryl group; substituted(C6-C10)aryl group; (C7-C9)aralkyl group; acyloxy or haloacyloxy group; (C1-C4)alkoxy group; C6-aryloxy group; (C7-C10)aralkyloxy group; (C1-C3)alkylthio group; C6-arylthio group; C6-arylsulfonyl group; (C7-C8)aralkylthio group; a heterocycle group; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group; (C2-C5)azacycloalkyl group; carboxy(C2-C4)alkylamino group; alpha-hydroxy(C1-C3)alkyl group; halo(C1-C3) alkyl group; acyl or haloacyl group; (C1-C4)alkoxycarbonylamino group; (C1-C4)alkoxycarbonyl group; RaRbamino(C1-C4)alkoxy group; or RaRbaminoxy group.

Those groups are then to be selected from further lists of second, third and fourth order in accordance with the hierarchical key set out in points 3.2.2.1.1 to 3.2.2.1.3 above.

3.2.2.3. If proviso (C) applies, the substituent R4' is selected from the following list of first order starting with "amino" on page 264, line 13 and ending with the "RaRbaminoxy group" on page 266, line 10 and indicating the alternative groups:

amino; monosubstituted amino; disubstituted amino; straight or branched (C1-C4)alkyl group; (C3-C6)cycloalkyl group; substituted (C3-C6)cycloalkyl group; (C6-C10)aryl group; substituted (C6-C10)aryl group; (C7-C9)aralkyl group; halo(C1-C3)alkyl group; a heterocycle group; RaRbamino(C1-C4)alkoxy group; or RaRbaminoxy group.

Those groups are then to be selected from further lists of second, third and fourth order in accordance with the hierarchical key set out in points 3.2.2.1.1 to 3.2.2.1.3 above.

3.2.2.4. If proviso (D) applies, the substituent R4' is selected from the following list of first order starting with "hydrogen" on page 266, line 18 and ending with the "(C1-C4)alkoxycarbony group" on page 270, line 13 and indicating the alternative groups:

hydrogen; straight or branched (C1-C4)alkyl group; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group; substituted (C3-C6)cycloalkyl group; (C6-C10)aryl group; substituted (C6-C10)aryl group; (C7-C9)aralkyl group; (C1-C4)alkoxy group; C6-aryloxy group; (C7-C10)aralkyloxy group; RaRbamino(C1-C4)alkoxy group; RaRbaminoxy group; (C1-C3)alkylthio group; C6-arylthio group; (C7-C8)aralkylthio group; a heterocycle group; hydroxy group; mercapto group; mono- or di- straight or branched (C1-C6)alkylamino group; halo(C1-C3)alkyl group; acyl or haloacyl group; or (C1-C4)alkoxycarbonyl group.

Those groups are then to be selected from further lists of second, third and fourth order in accordance with the hierarchical key set out in points 3.2.2.1.1 to 3.2.2.1.3 above.

3.2.3. The substituents R5 and R6 are defined on page 270, line 17 to page 273, line 16 following the same hierarchical order as set out in point 3.2.2.1 above in detail.

3.3. Therefore, claim 1 defines for a person skilled in the art clearly and unambiguously the subject-matter for which protection is sought and the scope thereof due to the hierarchical construction followed throughout that claim.

3.4. In the contested decision dependent claim 11 has been objected to under the heading of clarity since it comprised a long list of complex chemical names.

However, the chemical names objected to are drafted in accordance with the standards for chemical nomenclature conventional in the art. Therefore, they reveal unambiguously the corresponding chemical compounds to the person skilled in the art without any remaining unclarity.

3.5. For these reasons, in the Board's judgement, neither claim 1 nor claim 11 can be challenged with respect to clarity solely for their complexity and the Board concludes that those claims meet to that extent the requirements of Article 84 EPC.

4. In these circumstances, the examination not having been concluded and in view of the Appellant having requested remittal, the Board exercises its power under Article 111 (1) EPC to remit the case to the Examining Division for further prosecution.

5. When resuming examination proceedings, the Examining Division may consider whether or not example 132 is within the scope of claim 1 and whether or not the term "acyloxy or haloacyloxy group" on page 259, line 6 is correct, both objections having been noted in the decision under appeal, but not forming part of the reasons of the decision. Moreover, the Examining Division is directed to consider the matter whether or not the definition given inter alia on page 255, lines 20. to 22, which comprises a reference to S and Se heteroatoms, is consistent with the three heterocyclic formulae that follow in the claim.

6. Since the Appellant's main request succeeds there is no need for the Board to consider its auxiliary request for oral proceedings.

Order

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the first instance for further prosecution.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility